The decline in YiChang HEC ChangJiang Pharmaceutical's stock value despite its profitability may be due to its annual revenue decline. The company's recent total shareholder return suggests a potential turnaround, but the long-term loss raises caution.
Despite YiChang HEC ChangJiang Pharmaceutical's decent ROE hinting at promising fundamentals, its low earnings growth remains a concern, primarily considering it reinvests a significant part of profits. External factors might be inhibiting growth, but future earnings growth is predicted to dramatically improve.
Company's current P/S ratio may be worrying for investors due to slower revenue growth forecasts. Slower revenue growth could lower share prices, affecting the moderate P/S ratio.
While the recent positive outlook is encouraging, long-term performance injects caution. Prosperous business strategies indicated by annual revenue growth. Maintaining current overperformance level is key for future investment returns.
$东阳光长江药业(01558.HK)$1. Ownership structure; 2. Current and future sales markets of products on sale; 3. Data and progress of drugs under research; 4. Research institute market value and 10% equity; 5. Role of Blackstone convertible bonds; 6. Formally eliminated Where does the domestic capital go after the southbound trading? 7. The future trend of long and short funds
东阳光长江药业股票讨论区
暂无评论